TORONTO, Ontario and CAMBRIDGE, Massachusetts, March 13, 2023 (GLOBE NEWSWIRE) -- ProMIS Neurosciences Inc. (TSX: PMN) (Nasdaq: PMN), a biotechnology company focused on the generation and development of antibody therapeutics targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA), today announced an oral presentation and two onsite poster presentations at the upcoming American Academy of Neurology (AAN) Annual Meeting, which will be held on April 22-27, 2023 in Boston, MA. The presentations highlight ProMIS’ broad pipeline of next-generation neurodegenerative disease therapeutics, including data that further characterize lead drug AD candidate, PMN310, as well as preclinical optimization studies of an Alzheimer’s vaccine and data supporting RACK1 as a potential target in amyotrophic lateral sclerosis (ALS).

Oral Presentation:

Title: Rational Design of a Vaccine for Alzheimer’s Disease Using Computationally-Derived Conformational B Cell Epitopes to Selectively Target Toxic Amyloid-Beta Oligomers
Session: S26: Experimental Therapeutics in Dementia (abstract #4532)
Presenter: Dr. Johanne Kaplan
Date & Time: April 25, 2023 at 1:36 p.m. ET

Poster Presentations:

Title: Protection Against Toxic Amyloid-Beta Oligomers by PMN310, a Monoclonal Antibody Rationally Designed for Greater Therapeutic Potency in Alzheimer’s Disease
Session: P1: Aging and Dementia: Basic Science (abstract #4597)
Presenter: Dr. Johanne Kaplan
Date & Time: April 23, 2023 from 8:00 – 9:00 a.m. ET

Title: RACK1 Knockdown Is a Potential Therapeutic Target in ALS and FTLD-TDP
Session: P1: Aging and Dementia: Basic Science (abstract #3494)
Presenter: Dr. Neil Cashman
Date & Time: April 23, 2023 from 8:00 – 9:00 a.m. ET

About ProMIS Neurosciences Inc.

ProMIS Neurosciences Inc. is a development stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA. The Company’s proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform - ProMIS™ and Collective Coordinates - to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. ProMIS has offices in Toronto, Ontario and Cambridge, Massachusetts. ProMIS is listed on Nasdaq and the Toronto Stock Exchange under the symbol PMN.
For further information:

Visit us at www.promisneurosciences.com

Please submit media inquiries to info@promisneurosciences.com.

For Investor Relations, please contact:
Stern Investor Relations
Suzanne Messere, Managing Director
suzanne.messere@sternir.com 
Tel. 212 698-8801